Distinguished in Hyperparathyroidism

Dr. Michael J. Demeure

General Surgery
Hoag Clinic
1 Hoag Dr, 
Newport Beach, CA 
Distinguished in Hyperparathyroidism
Hoag Clinic
1 Hoag Dr, 
Newport Beach, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Demeure is a General Surgeon in Newport Beach, California. Dr. Demeure is rated as a Distinguished provider by MediFind in the treatment of Hyperparathyroidism. His top areas of expertise are Adrenal Cancer, Adrenocortical Carcinoma, Hyperparathyroidism, Thyroid Cancer, and Thyroidectomy.

His clinical research consists of co-authoring 54 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
General Surgery
Licenses
Surgery in CA
Hospital Affiliations
Hoag Memorial Hospital Presbyterian
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

HOAG CLINIC
1 Hoag Dr, Newport Beach, CA 92663

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 1/Phase 2
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: April 09, 2025
Intervention Type: Drug
Study Drug: ASTX295
Study Phase: Phase 1
Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies
Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies
Enrollment Status: Available
Publish Date: September 23, 2024
Intervention Type: Drug
Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers
Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Other, Drug, Radiation
Study Drugs: Selumetinib, Iodine-131
Study Phase: Phase 2
A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
Enrollment Status: Terminated
Publish Date: June 04, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes.
A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes.
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug
Study Drug: Nab-sirolimus
Study Phase: Phase 2
View 6 Less Clinical Trials

54 Total Publications

BRAF V600E Mutation Has Variable Tumor-Specific Effects on Expression of MAPK Pathway Genes That Could Affect Patient Outcome.
BRAF V600E Mutation Has Variable Tumor-Specific Effects on Expression of MAPK Pathway Genes That Could Affect Patient Outcome.
Journal: International journal of molecular sciences
Published: June 19, 2025
Similar Doctors
Elite in Hyperparathyroidism
Dr. Michael W. Yeh
General Surgery
Elite in Hyperparathyroidism
Dr. Michael W. Yeh
General Surgery

UCLA Associated General Surgeons

200 Medical Plz, Suite 214, 
Los Angeles, CA 
 (42.5 miles away)
310-825-6078
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Yeh is a General Surgeon in Los Angeles, California. Dr. Yeh is rated as an Elite provider by MediFind in the treatment of Hyperparathyroidism. His top areas of expertise are Hyperparathyroidism, Thyroid Cancer, Parathyroid Cancer, Parathyroidectomy, and Thyroidectomy.

Distinguished in Hyperparathyroidism
Dr. Masha Livhits
General Surgery
Distinguished in Hyperparathyroidism
Dr. Masha Livhits
General Surgery

UCLA Associated General Surgeons

100 Medical Plaza, Suite 310, 
Los Angeles, CA 
 (42.5 miles away)
310-267-7838
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Masha Livhits is a General Surgeon in Los Angeles, California. Dr. Livhits is rated as a Distinguished provider by MediFind in the treatment of Hyperparathyroidism. Her top areas of expertise are Hyperparathyroidism, Thyroid Cancer, Thyroid Nodule, Thyroidectomy, and Parathyroidectomy.

Distinguished in Hyperparathyroidism
Dr. Avital Harari
General Surgery
Distinguished in Hyperparathyroidism
Dr. Avital Harari
General Surgery

UCLA Associated General Surgeons

757 Westwood Plz, Fl 7, 
Los Angeles, CA 
 (42.5 miles away)
310-825-4381
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Avital Harari is a General Surgeon in Los Angeles, California. Dr. Harari is rated as a Distinguished provider by MediFind in the treatment of Hyperparathyroidism. Her top areas of expertise are Hyperparathyroidism, Parathyroid Hyperplasia, Osteitis Fibrosa, Parathyroidectomy, and Thyroidectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Demeure's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 14 Advanced Conditions
    View All 11 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile